US8829013 — Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Method of Use · Assigned to Incyte Corp · Expires 2028-06-12 · 2y remaining
What this patent protects
This patent protects salt forms of the Janus kinase inhibitor RUXOLITINIB PHOSPHATE for use in treating diseases related to Janus kinase activity.
USPTO Abstract
The present invention provides salt forms of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that are useful in the modulation of Janus kinase activity and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-1201 |
— | ruxolitinib-phosphate |
U-1622 |
— | ruxolitinib-phosphate |
U-1201 |
— | ruxolitinib-phosphate |
U-1622 |
— | ruxolitinib-phosphate |
U-1622 |
— | ruxolitinib-phosphate |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.